Ocugen Inc. (OCGN)
0.64
-0.05 (-7.11%)
At close: Apr 03, 2025, 3:59 PM
0.64
-0.09%
After-hours: Apr 03, 2025, 05:04 PM EDT
-7.11% (1D)
| Bid | 0.64 |
| Market Cap | 188.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | -3.22 |
| Forward PE | -2.67 |
| Analyst | Buy |
| Ask | 0.65 |
| Volume | 3,496,599 |
| Avg. Volume (20D) | 4,000,610 |
| Open | 0.65 |
| Previous Close | 0.69 |
| Day's Range | 0.62 - 0.67 |
| 52-Week Range | 0.52 - 2.08 |
| Beta | 3.89 |
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 3, 2014
Employees 95
Stock Exchange NASDAQ
Ticker Symbol OCGN
Website https://www.ocugen.com
Analyst Forecast
According to 3 analyst ratings, the average rating for OCGN stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 986.79% from the latest price.
Stock Forecasts8 months ago
-7.8%
Ocugen shares are trading lower after the company ...
Unlock content with
Pro Subscription
8 months ago
-4.08%
Ocugen shares are trading lower after the company announced an underwritten public offering.
